| Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease CS Hourigan, LW Dillon, G Gui, BR Logan, M Fei, J Ghannam, Y Li, ... Journal of Clinical Oncology 38 (12), 1273-1283, 2020 | 345 | 2020 |
| Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry KA Oetjen, KE Lindblad, M Goswami, G Gui, PK Dagur, C Lai, LW Dillon, ... JCI insight 3 (23), 2018 | 166 | 2018 |
| Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes—long-term follow-up of … BL Scott, MC Pasquini, M Fei, R Fraser, J Wu, SM Devine, DL Porter, ... Transplantation and cellular therapy 27 (6), 483. e1-483. e6, 2021 | 79 | 2021 |
| DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant LW Dillon, G Gui, KM Page, N Ravindra, ZC Wong, G Andrew, ... Jama 329 (9), 745-755, 2023 | 63 | 2023 |
| Heterogeneity in refractory acute myeloid leukemia S Horibata, G Gui, J Lack, CB DeStefano, MM Gottesman, CS Hourigan Proceedings of the National Academy of Sciences 116 (21), 10494-10503, 2019 | 55 | 2019 |
| Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia M Goswami, G Gui, LW Dillon, KE Lindblad, J Thompson, J Valdez, ... Journal for immunotherapy of cancer 10 (1), 2022 | 44 | 2022 |
| Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia H Çelik, KE Lindblad, B Popescu, G Gui, M Goswami, J Valdez, ... Blood Advances 4 (2), 367-379, 2020 | 36 | 2020 |
| Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia KE Lindblad, J Thompson, G Gui, J Valdez, T Worthy, H Tekleab, ... Blood 132 (Supplement 1), 1437-1437, 2018 | 31 | 2018 |
| Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from nonmalignant clonal hematopoiesis LW Dillon, J Ghannam, C Nosiri, G Gui, M Goswami, KR Calvo, ... Blood cancer discovery 2 (4), 319-325, 2021 | 29 | 2021 |
| Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome LW Dillon, G Gui, BR Logan, M Fei, J Ghannam, Y Li, A Licon, EP Alyea, ... JCO Precision Oncology 5, 265-274, 2021 | 20 | 2021 |
| EGFR activates a TAZ-driven oncogenic program in glioblastoma M Gao, Y Fu, W Zhou, G Gui, B Lal, Y Li, S Xia, H Ji, CG Eberhart, ... Cancer research 81 (13), 3580-3592, 2021 | 13 | 2021 |
| Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells Q Li, Y Feng, Y Xue, X Zhan, Y Fu, G Gui, W Zhou, JP Richard, A Taga, ... Molecular neurodegeneration 17, 1-18, 2022 | 12 | 2022 |
| Frondoside a inhibits an MYC-driven medulloblastoma model derived from human-induced pluripotent stem cells Y Xue, Y Fu, F Zhao, G Gui, Y Li, S Rivero-Hinojosa, G Liu, Y Li, S Xia, ... Molecular cancer therapeutics 20 (6), 1199-1209, 2021 | 12 | 2021 |
| Pre-MEASURE: Multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in … CS Hourigan, LW Dillon, G Gui, N Ravindra, Z Wong, G Andrew, ... Journal of Clinical Oncology 40 (16_suppl), 7006-7006, 2022 | 8 | 2022 |
| Human bone marrow assessment by singlecell RNA sequencing, mass cytometry, and flow cytometry. JCI Insight 3: e124928 KA Oetjen, KE Lindblad, M Goswami, G Gui, PK Dagur, C Lai, LW Dillon, ... | 7 | 2018 |
| Measurable residual disease assessment as a surrogate marker in new drug development in acute myeloid leukemia G Gui, CS Hourigan The Cancer Journal 28 (1), 73-77, 2022 | 6 | 2022 |
| Pre-and post-transplant measurable residual IDH mutations are not associated with relapse in patients with IDH-mutated AML N Ravindra, LW Dillon, G Gui, CS Hourigan, AJ Ambinder Blood 140 (Supplement 1), 3391-3392, 2022 | 2 | 2022 |
| Pre-MEASURE: FLT3-ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission LW Dillon, G Gui, N Ravindra, Z Wong, G Andrew, D Mukherjee, SL Zeger, ... medRxiv, 2022.10. 21.22281322, 2022 | 2 | 2022 |
| Measurable residual disease before reduced-intensity allogeneic transplantation in patients with myeloid malignancy G Gui, LW Dillon, CS Hourigan Journal of Clinical Oncology 39 (21), 2413-2415, 2021 | 2 | 2021 |
| Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic … N Ravindra, LW Dillon, G Gui, M Smith, LP Gondek, RJ Jones, A Corner, ... Bone marrow transplantation 59 (3), 428-430, 2024 | 1 | 2024 |
